Mitochondrial Toxicity: Designing Novel Screening Methods to Reduce NCE Attrition
Guest Speaker:
Yvonne Will
R&D, Exploratory Safety Differentiation-
Cell Based Assays,
Pfizer
Webinar Abstract:
Mitochondria have been increasingly recognized as a target of drug toxicity, resulting in the disruption of bioenergetics and causing oxidant stress. Drug-induced mitochondrial toxicity is implicated in organ toxicity in liver, kidney, CNS, cardiovascular, and skeletal muscle. Certain underlying disease states like diabetes, infections, or neurodegenerative diseases can greatly alter mitochondrial function and make the mitochondria more vulnerable to drug toxicity.
You will learn:
- A variety of new technologies capable of measuring mitochondrial function in a rapid throughput format
- How immunocapture of individual electron transport chain proteins can identify inhibitors of mitochondrial electron transport and metabolic profiling
- About the strength and limitations of new HTS applicable screens and recommendations of where to position these assays within drug development
Assay:
Energy Expenditure: Shift from OXPHOS to Compensatory Glycolysis
Mitochondrial Function:Acute OCR drug dose curve
Log In to View on-Demand